[7] CKD 1. Time: the diagnosis was only based on the data or information within the active surveillance period. 2. Diagnosis: CKD was defined as abnormalities of kidney structure or function that was present for >3 months and was classified based on GFR category (stage 1 to 5). We excluded the patients with CKD stage 5 in this study. Therefore, the patients had either "no CKD or CKD stage 1" or "CKD stage 2, 3, or 4". 4. We reviewed the charts to exclude possible acute changes of the renal function.
[8] Anemia 1. Time: the diagnosis was only based on the data or information within the active surveillance period. 2. Diagnosis: anemia was defined as hemoglobin < 12g/L in non-pregnant women and < 13 g/L in men. 3. We reviewed the charts to exclude possible acute changes, such as bleeding or major trauma.
[9]
Advanced fatty liver 1. Time: the diagnosis was only based on the data or information within the active surveillance period. 2. Diagnosis: advanced fatty liver was according to fatty liver echogenicity, and the severity of fatty liver echogenicity was graded as grade 0 to 3 (none, mild, moderate, and severe). We considered the moderate or severe fatty liver echogenicity as advanced fatty liver. 3. The abdominal ultrasonography was conducted by an independent radiologist or hepatologist every 3 to 6 months. We retrospectively evaluated the formal reports and the images for confirmation.
[10] [15] , the range referred to minial and maximal values. b In the supplemental reference [16] , the range referred to values that were observed in extrapolated data. Abbreviations: CHB, chronic hepatitis B; DM, diabetes mellitus; ETV, entecavir; IFN, interferon; IL, interleukin; IP-10, interferon--inducible protein of 10 kDa; IQR, interquartile range; NA, not available; SFTS, severe fever with thrombocytopenia syndrome; TGF, transforming growth factor.
Figure S1. Comparison of IP-10 levels between the groups categorized by with or without prediabetes or T2DM. The lines indicate the median with the interquartile range. IP-10, interferon--inducible protein of 10 kDa; T2DM, type 2 diabetes mellitus. Figure S2 . A theoretical hypothesis of two conditions. From (A) to (C), the combination of the immune response and entecavir suppressed but did not eradicate HBV; therefore, serum HBsAg levels decreased steadily but slowly. (D) When IR occurs, it promotes hepatic fatty changes and disturbs the immune function, which is evident from elevated IP-10 levels; meanwhile, IR hindered the HBsAg decline (panel C and D compared). From (E) to (F), the IR is sustained and the advanced fatty liver occurs. Furthermore, an inflammation-prone immune system promoted fibrosis, as evidenced from the elevated fibrosis-4 index. Once the liver parenchyma, where HBV resides, shrinks significantly, the downswing of HBsAg accelerates again. The events in panels D, E, and F could occur simultaneously. HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IP-10, interferon-inducible protein of 10 kDa; IR, insulin resistance.
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